Articles On Telix Pharmaceuticals (ASX:TLX)

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is pushing higher. At the time of writing, the benchmark index is up 0.5% to 7,082.4 points. Four ASX shares that are climbing more than most...

Telix Pharmaceuticals (ASX:TLX) has announced that its bone marrow conditioning investigational candidate TLX66 has met the objectives of a phase I/IIa trial in demonstrating the initial safety profile in patients with AL amyloidosi...

Summary Oncology firm Telix Pharmaceuticals has entered into an exclusive commercial distribution agreement to distribute its product in the German market. Proteomics has secured a significant contract for pharmacokinetic testing, whil...

Summary Telix Pharmaceuticals signs distribution agreement with Germany based company Proteomics International bags new pharmacokinetic testing contract com accomplishes A$428 million institutional entitlement offer Citi hikes PT for...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is on the move today. This follows the biotechnology company’s announcement that it has inked a new lucrative deal. At the time of writing, the Telix Pharmaceuticals share price is tradi...

Telix (ASX:TLX) has announced an exclusive commercial distribution agreement with Eckert & Ziegler for its prostate cancer imaging product Illuccix for the German market.

Telix Pharmaceuticals (ASX:TLX) says it has been granted HREC approval and received CTN clearance by the TGA for a phase 3 clinical trial of its PSMA targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab).

For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s b...

Summary Oncology player Telix Pharmaceuticals has commenced Phase 3 clinical trial of its prostate cancer therapy candidate. Polymer implants manufacturer Osteopore Limited has obtained CE certification for a significantly broader rang...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price will be in focus today after the company announced its prostate cancer therapy has been approved for stage III clinical trials. Shares in the company closed last session trading at $3.94...

Telix Pharmaceuticals (ASX:TLX) has announced an agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.

Wall Street bounces back All major indices in the US have bounced back, after falling the previous day. Both the Dow Jones and S&P 500 rose by 0.93%, while tech heavy NASDAQ also rose by 1.19%. It was a broad-based increase across all s...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has the wobbles today after the company shared news of a successful trial.   The biopharmaceutical company announced that its kidney cancer imaging product’s Japanese clinical study met...

Global equities tumble All major world indices tumbled overnight as COVID-19 deaths spiked in India and elsewhere. In the US, the Dow Jones dropped 0.75%, S&P500 shed 0.68%, while tech heavy NASDAQ also tumbled by 0.92%. Europe recorded...

19 Apr 2021 - Telix Pharmaceuticals (ASX:TLX) has announced the launch of the "Nobody Left Behind" ("NOBLE") Registry.

Source: Have a nice day Photo, Shutterstock Summary Telix Pharmaceuticals has announced the launch of NOBLE Registry of its prostate cancer imaging agent. Global healthcare company Ramsay Health Care confirms the funding guarantee arr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With stock...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is storming higher this morning. At the time of writing, the clinical-stage biopharmaceutical company’s shares are up 5% to $4.24. Why is the Telix share price rising? Investors have bee...

Telix Pharmaceuticals (ASX:TLX) has announced an agreement with contract development and manufacturing organisation Grand River Aseptic Manufacturing (‘GRAM’) to perform commercial-scale manufacturing of its Illuccix product.

31 Mar 2021 - Telix Pharmaceuticals (ASX:TLX) has completed an agreement with contract development and manufacturing organisation Grand River Aseptic Manufacturing to perform comme…

Michael Gable is an expert guest commentator for the Finance News Network, presenting “Stock Watch” each week – covering stock tips and shares on the Australian market (ASX). This video is dated 22 March 2021.  Shares covered: NASDAQ, (ASX:...

Source: Enjoy The Life, Shutterstock Summary ASX 200 increased 0.8% on Friday, however it edged lower Monday morning with a decline of almost 33% following the quarterly rebalance announcement. ASX 200 saw 6 new companies being added...

Source: Josep Suria, Shutterstock  Healthcare, one of the biggest and most convoluted sectors in the trade market, is made up of a wide assortment of companies dealing with pharma, medical, fitness and other healthcare facilities and produ...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is sliding 4.3% today after the company released its FY20 results. The broader S&P/ASX 200 (ASX: XJO) is currently down 2.3% at the time of writing. Telix is a late clinical-stage rad...

Telix Pharmaceuticals (ASX.TLX) has announced that its Japanese subsidiary and partner Kanazawa University have received Clinical Trial Notification clearance to commence a phase one trial of its prostate cancer imaging product TLX5...

Australian company Telix Pharmaceuticals (ASX:TLX) has announced the Ministry of Health of the Czech Republic has become the first European health authority to grant a national authorisation allowing the use of TLX591-CDx.

Summary Telix Pharmaceuticals has obtained national authorisation for its prostate cancer imaging product, TLX591-CDx. With this national authorisation, Czech physicians can use the product even before European marketing approval is gr...

Telix Pharmaceuticals (ASX:TLX) has announced a research cooperation agreement with Heidelberg University Hospital in Germany (UKHD) to develop next-generation theranostic radiopharmaceuticals for urologic oncology.

The OC Micro-Cap Fund was a strong performer during the final quarter of 2020. According to its most recent quarterly update, the fund manager delivered a 17.5% return for investors during the three months ended 31 December. This stretched...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to start the week strongly. At the time of writing, the benchmark index is up 0.4% to 6,825.7 points. Four ASX shares that have failed to follow the market higher today a...

25 Jan 2021 - Bio-tech company Telix Pharmaceuticals (ASX:TLX) Phase 3 clinical trial of its renal cancer diagnostic imaging product, Zircon has commenced in the US.

Will the share price of Telix Pharmaceuticals Ltd (ASX: TLX) go up after announcing patient news? What’s Telix? Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using mole...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has come under pressure on Monday morning and is dropping lower. At the time of writing, the clinical stage biopharmaceutical company’s shares are down 0.5% to $4.51. Why is the Telix sh...

Telix Pharmaceuticals (ASX:TLX) and partner ARTMS have announced they have successfully produced Telix's prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).

Over the past 12 months, the Telix Pharmaceuticals Ltd (ASX: TLX) share price has posted massive gains exceeding 150%. The Telix share price kicked off 2020 at $1.53, closed the year at $3.78 and is currently sitting at $3.86 per share. So...

Telix Pharmaceuticals plans to accelerate development of its radiopharmaceutical to treat the most aggressive form of brain cancer after encouraging ... Read More The post Initial trial results bolster evidence for Telix’s brain cancer trea...

Summary Biopharmaceutical player Telix Pharmaceuticals files a New Drug Submission for TLX591-CDx. The Company has entered in an exclusive scientific and clinical research collaboration with Mauna Kea. The collaboration will build adv...

Biopharma Telix Pharmaceuticals Ltd (ASX: TLX) share price is trading lower this morning, despite the company announcing the completion of its acquisition of Swiss-based company, TheraPharm. At the same time, the company also announced tha...

Summary The intensity of adoption of tech-enabled health solutions has shot up amidst government restrictions and infection risks amidst COVID-19. Burgeoning demand for healthcare products kept healthcare stocks under the spotlight in...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is trading lower at open today, despite a positive development in its lead drug candidate. Telix announced that the United States Food and Drug Administration (FDA) will begin reviewing...

The TGA has granted Telix Pharmaceuticals' (ASX:TLX) prostate cancer imaging product TLX591-CDx priority review status.

Image Source: Shutterstock Summary Telix Pharmaceuticals announced that its application for TGA determination received priority review status. This status means an acceleration in product review as well as approval timeframe. There i...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is slipping today, down 2.5% in afternoon trading. This comes despite the company reporting it had received priority review status from Australia’s Therapeutic Goods Administration (TGA)...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.2% to 6,603.5 points. Four shares that are climbing more than most today are listed below. Her...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher after the company announced a new phase in its drug trials. The company confirmed it will proceed with the Phase III of ProstACT study for its TLX591 drug, a prostate ca...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and is dropping lower. The benchmark index is currently down 0.3% to 6,570.8 points. Four shares that have not let that hold them back are listed belo...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher again on Wednesday after the release of two positive announcements. At the time of writing, the nuclear medicine-focused biopharmaceutical company’s shares are up 9% to...

Australian biotechnology company Telix Pharmaceuticals has announced it will acquire Swiss-German counterpart TheraPharm for its portfolio of potential diagnostics and treatments for haematological diseases like blood cancer.

Summary Telix signed an agreement with Scintec to acquire TheraPharm GmbH. An upfront payment of A$16.5 million would be made for this acquisition. The first and second earn-out component would each be of A$8.1 million, respectively....

30 Nov 2020 - Telix Pharmaceuticals (ASX:TLX) has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH.